Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor

JAAD Case Rep. 2023 Jun 17:38:64-67. doi: 10.1016/j.jdcr.2023.06.009. eCollection 2023 Aug.

Authors

Carine M Lama¹, Miguel A Hernandez-Rovira¹, Neha Mehta-Shah², Aaron Russell^{3

4}, Amy C M Musiek³

Affiliations

¹ Washington University School of Medicine, St. Louis, Missouri.
² Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
³ Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
⁴ Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.

No abstract available

Keywords: Janus kinase inhibitor; Sézary syndrome; cutaneous T-cell lymphoma; mogamulizumab-associated rash.

Publication types

Case Reports